Objective: The hypothesis is that partial nuclear factor-kappaB (NF-B) inhibition can alleviate cardiopulmonary dysfunction associated with ischemia and reperfusion injury following cardiopulmonary bypass and deep hypothermic circulatory arrest (CPB/ DHCA) in a pediatric model.
I schemia and reperfusion injury to the immature myocardium that occurs during repair of congenital heart disease remains a significant contributor to perioperative morbidity and mortality. Despite the use of inotropes in the postoperative period, a low cardiac output state may occur in up to 30% of neonates and infants. Underlying this process is overall myocardial depression including both systolic and diastolic dysfunction. Although often transient, more permanent injury in the form of necrosis and/or apoptosis might occur. Pulmonary dysfunction is frequently present and added to the myocardial dysfunction exacerbates the low cardiac output state.
We have previously demonstrated that administration of glucocorticoids, which maintain the cellular levels of the endogenous calpain inhibitor calpastatin (1, 2) , or the administration of a peptide calpain inhibitor (3) markedly attenuates myocardial dysfunction and reduces pulmonary hypertension in a piglet model of cardiopulmonary bypass and deep hypothermic circulatory arrest (CPB/DHCA). The mechanism by which calpain inhibi-tion improves cardiopulmonary function is not entirely known. A proposed mechanism is that increased calpain activity stimulates nuclear factor-kappaB (NF-B) translocation from the cytoplasm to the nucleus where NF-B binding to DNA leads to up-regulation of various inflammatory and cell death regulators (4) .
Calpains are calcium-dependent cysteine proteases regulated by the endogenous-specific calpain inhibitor, calpastatin. Calpain-mediated cleavage regulates the activity of diverse substrates including kinases, cytoskeletal proteins, apoptotic cascade members, and a number of transcription regulatory proteins, such as NF-B. Calpain also systematically degrades troponin I (TnI), the inhibitory component of the cardiac troponin complex, which mediates calcium dependence of cardiac contraction (5) . Selective proteolysis of TnI is proposed to lead to contractile dysfunction after myocar-dial reperfusion, resulting in myocardial stunning (6, 7) that can be limited through calpain inhibition (1) .
In quiescent cells, NF-B in the cytosol remains bound to the inhibitor kappa B (IB) family of proteins. On stimulation, IB is phosphorylated and degraded by proteases, including calpain. Released NF-B translocates to the nucleus and binds specific DNA sequences to regulate target genes. In some cell types, NF-B activation is markedly reduced by calpain inhibitors (8 -10) . Calpains might also inactivate NF-B by directly proteolysis (4) .
Regulation of programmed cell death by NF-B appears to be a balance of procell vs. anti-cell survival signals (11) . A basal level of NF-B activity suppresses apoptosis and necrosis through expression of caspase inhibitors, anti-apoptotic Bcl-2 family members, and antioxidants; but elevated NF-B activity leads to inflammatory gene expression and cellular injury (12) .
Endothelin-1, a potent vasoconstrictor, is also regulated in part by NF-B. In previous studies with glucocorticoid administration and calpain inhibition, there was a reduction in pulmonary hypertension after CPB that was associated with a decrease in plasma endothelin-1 (3, 13) . In addition, an endothelin-1 receptor antagonist also ameliorated pulmonary hypertension associated with ischemia and reperfusion in the piglet model (14) .
Previous studies by our research group indicate that glucocorticoids administered before CPB can alleviate CPB-DHCA-associated cardiopulmonary dysfunction. The improvement in function is accompanied by decreased calpain activity in the heart and lungs and maintenance of endogenous levels of calpastatin (1) . Direct administration of a peptide inhibitor of calpain during CPB-DHCA also improved cardiopulmonary function and decreased NF-B activity in the heart (3) . Therefore, we conducted these experiments to determine whether administration of a NF-B inhibitor to alleviate the CPB-DHCA-induced rise in NF-B activity would reduce cardiopulmonary dysfunction and cellular injury in a piglet model of CPB-DHCA.
METHODS
Animal Model. All animals received humane care in compliance with the Principles of Laboratory Animal Care, formulated by the National Society for Medical Research, and the Guide for the Care and Use of Laboratory Animals, prepared by the Institute of Laboratory Animals Resources and published by the National Institutes of Health (NIH Publication No. 86 -23, revised 1985) . The Institutional Animal Care and Use Committee at Cincinnati Children's Hospital Research Foundation also approved the protocol.
Piglets weighing 5-7 kg were anesthetized, mechanically ventilated, and subjected to CPB and DHCA as previously described (1, 2, 13) . Pentobarbital infusion (20 mg⅐kg Ϫ1 ⅐hr Ϫ1 ), intermittent fentanyl citrate (10 g⅐kg Ϫ1 ⅐hr Ϫ1 ), and pancuronium bromide (0.1 mg⅐kg Ϫ1 ⅐hr Ϫ1 ) were used with doses sufficient to maintain deep general anesthesia. Pressure catheters (Millar Instruments, Houston, TX) were placed in the pulmonary artery and in the right and left ventricles (RV and LV). Six piezoelectric crystals were placed in the myocardium at the anterior, posterior, base, and apex of the LV and at the widest point of RV and LV free walls. The distances between all six crystals on three axes were measured by sonomicrometry. Sonolab data collection and Cardiosoft analysis software monitored cardiac function (Sonometrics, ON, Canada). Pressure-volume loops generated during preload reduction by transient vena caval occlusion allowed for measures of cardiac contractility relatively independent of heart rate and afterload. Ventricular Ϯ dP/dt, LV Tau, oxygen delivery, and preload recruitable stroke work relation were calculated. Respiratory function was monitored by CO 2 SMO Plus respiratory profile system (Novametrix, Wallingford, CT). Dynamic compliance, airway resistance, and expired CO 2 and O 2 were monitored, and pulmonary vascular resistance (PVR) ͓80 ϫ (mean pulmonary artery pressure Ϫ central venous pressure)/cardiac output͔ was calculated. Baseline measurements of pulmonary and cardiac function are taken after a 30minute equilibration period.
Animals were administered heparin and placed on CPB with cannulation via the carotid artery and right atrial appendage. The CPB prime consisted of 800-mL direct-drawn whole porcine blood (Animal Biotech Industries, Danboro, PA). Hematocrit on CPB was maintained at 25% to 30% and calcium at 0.6 -0.8 mg/L, with a flow rate of 100 mL⅐kg Ϫ1 ⅐min Ϫ1 . Once on CPB, animals were cooled to a rectal temperature of 18°C over ϳ40 minutes. The bypass circuit was then turned off, and the animal was packed in ice. The heart was protected with topical cold saline and ice. Circulatory arrest was maintained for 120 minutes. Cardiopulmonary bypass was reinstituted, and the animals were warmed to 38°C over 45 minutes on CPB. Piglets were removed from CPB and maintained under anesthesia for 120 minutes. Blood gases were monitored periodically throughout the experiment (Bayer Diagnostics). Aortic and pulmonary arterial blood samples from each animal were collected at baseline, 1 hour, and 2 hours after CPB/DHCA. Animals were randomly divided into the experimental groups:
1. no CPB/DHCA Controls (n ϭ 3), 2. CPB/DHCA Controls, no treatment (n ϭ 8), and 3. CPB/DHCA SN50, NF-B translocation inhibitor administered before CPB/DHCA (n ϭ 6). Animals were administered a single dose of 100 g/kg of SN50 (Alexis Biochemicals, San Diego, CA), an inhibitor of NF-B translocation, 1 hour before CPB by intravenous injection.
This dose was selected from preliminary studies to reduce NF-B activity in the heart 120 minutes after CPB/DHCA to near baseline levels without abolishing NF-B activity.
NF-B Activity. NF-B in nuclear extracts (10 g) from the LV myocardium was assessed with a transcription factor assay kit according to the manufacturer's instructions (Active Motif, Carlsbad, CA). Antibodies for the activated forms of the p50 and p65 (rel A) subunits of NF-B were included in the assay. The detection limit for the assay is 0.4 ng recombinant p50 or p65 protein.
Endothelin-1 Measurements. Blood samples were immediately centrifuged at 4°C, and plasma was frozen at Ϫ80°C for later analysis. A commercial endothelin-1 immunoassay kit (R&D Systems, Minneapolis, MN) was used to measure endothelin-1 concentration in plasma.
Myocardial Protein Immunoblot Analyses. Collected tissues were homogenized in 10 mmol/L 3-͓N-morpholino͔ propane sulfonic acid buffer and stored at Ϫ80°C until used. Western blots were performed with 30-g total proteins separated on 4% to 12% acrylamide bis-tris gels (Invitrogen, Carlsbad, CA) by sodium dodecyl sulfate polyacrylamide gel electrophoresis and then immunoblotted with antibodies for calpain I and II (Calbiochem, San Diego, CA), calpastatin (Chemicon, Temecula, CA), IB-␣ (Santa Cruz Biotechnology, Santa Cruz, CA), and glyceraldehyde phosphate dehydrogenase (GAPDH, Chemicon). Secondary antibodies were alkaline phosphatase-conjugated goat anti-rabbit or anti-mouse IgG. Proteins were visualized with a chemiluminescent detection system according to the manufacturer's instructions (Invitrogen). Protein levels are reported as a ratio of target protein to GAPDH levels on the same immunoblot to correct for background effects.
TnI Degradation. TnI degradation in adult stunned myocardium occurs as the result of activation of calpains (6) , and our research group reported that TnI degradation occurred in this model after CPB/DHCA (1). Cardiac myofibrils were isolated from myocardial tissue collected at the end of the experiment (15) . Myofibril proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membrane. Membranes were blocked and incubated with TnI antibody recognizing all of the previously reported degradation products (Research Diagnostics, Flanders, NJ). Immunoblotting was carried out by standard chemiluminescent procedures. The degree of degradation was measured as the percent of total TnI in each immunoblot lane that was detectable in degraded and complexed bands.
Statistical Analysis of Data. Repeatedmeasures analysis of variance was used to analyze serial data over time, and post hoc comparisons made by Fisher's post hoc least significant difference test were used when appropriate to evaluate differences between individual time points within treatment groups. Comparisons between treatments were made by analysis of variance, with a p value Յ 0.05 considered significant. Personnel blinded to the treatment group status conducted analyses using Statview 4.01 software (Abacus Concepts, Berkeley, CA). Data are reported as means Ϯ standard deviations.
RESULTS
NF-B Activity. The administration of SN50 decreased NF-B activity levels in nuclear extracts from LV myocardium 120 minutes after CPB/DHCA compared with CPB/DHCA controls (0.18 Ϯ 0.1 vs. 0.7 Ϯ 0.16 absorbance units p Ͻ 0.001, Fig. 1 ). Hearts from SN50-treated animals had NF-B activity levels slightly lower than control animals that did not undergo CPB/DHCA (0.18 Ϯ 0.1 vs. 0.368 Ϯ 0.04 absorbance units, p ϭ 0.05). Immunoblots of LV myocardial homogenates indicated that SN50 treatment maintained IB␣ protein at higher levels than in untreated animals (0.79 Ϯ 0.14 vs. 0.59 Ϯ 0.14 ratio of target to GAPDH, p ϭ 0.04) 120 minutes after CPB/DHCA (Fig. 2) .
Cardiopulmonary Function. SN50 inhibition of NF-B prevented the increase from baseline in PVR associated with the CPB/DHCA untreated controls. In the CPB/DHCA, SN50 group PVR (dyne⅐sec Ϫ1 ⅐cm Ϫ5 ) was not different at baseline compared with 120 minutes after CPB/DHCA (100 Ϯ 24 vs. 169 Ϯ 88, p ϭ 0.1). However, PVR in the CPB/ DHCA controls increased from 124 Ϯ 59 at baseline to 369 Ϯ 104 at 120 minutes after CPB/DHCA (p ϭ 0.001, Fig. 3 ).
Myocardial contractile function, measured as LV maximum and minimum derivative of the change in pressure/ derivative of the change in time (dP/dt), was preserved with SN50 administration after CPB/DHCA (Fig. 4) . Maximum dP/dt in the CPB/DHCA controls decreased from 1243 Ϯ 242 mm Hg/sec at baseline to 964 Ϯ 251 mm Hg/s at 120 minutes after CPB/DHCA (p ϭ 0.04), whereas it did not differ in the SN50-treated animals (p ϭ 0.09). Minimum dP/dt showed a similar trend. Left ventricular Tau, the time-constant of relaxation, was unchanged from baseline in SN50-treated animals (p ϭ 0.06), whereas it was elevated from baseline (61.2 Ϯ 12 msec) at 120 minutes after CPB/DHCA (102.2 Ϯ 21 msec) in untreated animals ( Fig. 5 ). Preload recruitable stroke work (PRSW) was also better maintained in SN50 hearts compared with controls at 120 minutes after CPB/DHCA (Fig. 6 ). The depression in oxygen delivery in CPB/DHCA controls from baseline (99 Ϯ 26 mL/min) to 120 minutes after CPB (63 Ϯ 20 mL/min, p Ͻ 0.0001) was ameliorated with SN50 administration (76 Ϯ 13 mL/min at baseline vs. 75 Ϯ 5 mL/min at 120 minutes after CPB/DHCA, p ϭ 0.9). Cardiac function parameters are further defined in Table 1 .
Plasma Endothelin-1 Levels. Plasma endothelin-1 levels increased with CPB/ DHCA from 2.1 Ϯ 0.37 pg/mL at baseline to 14.2 Ϯ 5.7 pg/mL at 120 minutes (p ϭ 0.004, Fig. 7) . A large portion of the elevation in endothelin-1 levels was alleviated by NF-B inhibition, but there was still a rise from baseline endothelin-1 levels (1.2 Ϯ 0.76 pg/mL) at 120 minutes after CPB/DHCA (4.5 Ϯ 2 pg/mL, p ϭ 0.005 vs. baseline, p ϭ 0.003 vs. CPB/ DHCA controls).
Calpain and Calpastatin Activity and Protein Levels. SN50 treatment did not affect the densitometry ratio of calpain I and II to GAPDH protein levels in LV myocardium at 120 minutes after CPB-DHCA (p Ͼ 0.05, Fig. 8 ). However, calpastatin protein was higher in SN50treated animals than in the untreated group (0.35 Ϯ 0.06 vs. 0.20 Ϯ 0.07 densitometry ratio of calpastatin to GAPDH, p ϭ 0.05).
TnI Degradation. Total TnI degradation and the main 26-kD degradation product in the LV myofibrils isolated 120 minutes after CPB/DHCA were significantly lower in SN50-treated animals than in controls (Fig. 9 ). The TnI detected in all the degradation bands for the CPB/DHCA controls was 36.2% Ϯ 2.4% of the total detected compared with 27.3% Ϯ 3.5% for the SN50-treated animals (p ϭ 0.007). The major TnI degradation product at 26 kD was 15.5% Ϯ 4.3% of the total TnI for the untreated animals and only 9.3% Ϯ 1.4% in the SN50-treated animals (p ϭ 0.01).
DISCUSSION
In the early minutes of myocardial reperfusion, a sudden influx of calcium activates numerous pathways resulting in myocyte dysfunction and injury and even myocyte death secondary to contracture (16) . Calcium overload associated with ischemia and reperfusion activates calpains and reduces calpastatin levels (17, 18) . Until recently, no in vivo studies have examined calpain regulation of the NF-B pathway during reperfusion of immature myocardium. In prior studies, we demonstrated an association between calpain inhibition, maintenance of IB␣ protein in the cytosol, and decreased NF-B activity (3) . These changes were associated with reduced markers of inflammation (2) and apoptotic cell injury (19) . Having demonstrated an effect of calpain inhibition on NF-B activation, we attempted to compare the functional recovery seen with calpain inhibition with changes in NF-B activity. In this study, the cardiopulmonary func-tional recovery with NF-B inhibition was similar to that observed in calpain inhibition studies.
Glucocorticoid treatment, which prevented the breakdown of calpastatin in myocardium after CPB/DHCA (1) and direct administration of a peptide calpain inhibitor (2), maintained IB␣ protein levels in the cytosol and reduced NF-B binding to DNA in the nucleus. With various modes of activation, IB␣ underwent serine phosphorylation, ubiquitination, and degradation through a wellcharacterized proteosomal pathway (20) . However, recent studies indicated that two parallel pathways of IB degradation exist: the proteosomal pathway and a calpain-dependent pathway that degraded IB␣ after phosphorylation (21) , probably regulated by tyrosine instead of serine phosphorylation (9, 22) . In specific cell types, such as IgM ϩ B cells, IB␣ degradation through calpain-regulated mechanisms was more important than the proteosome pathway (8) . Tyrosine kinase regulation of NF-B activation was especially evident during ischemic preconditioning in the heart (23, 24) . As neonatal hearts have higher levels of calpain than do adults, a possible reliance on calpainmediated IB regulation could exist. However, the administration of high doses of corticosteroids to patients during CPB remains controversial (25) . A number of studies indicate that high-dose steroids can result in detrimental postoperative alterations. Therefore, the goal would be to target specific therapies to the beneficial steroid pathways and not to activate the broad spectrum of effects associated with steroid administration.
A basal level of NF-B might be necessary to maintain the prosurvival signal in some cell types, for instance, NF-Bp65 Ϫ/Ϫ mice die at mid-gestation because of severe apoptosis in the liver (26) . Stimuli inducing NF-B above this basal level, however, may overpower the prosurvival signal and result in cell injury or death. Although targeting a specific activity level for NF-B would be clinically challenging, the potential to affect one pathway activating NF-B, such as the calpain-mediated pathway, while leaving other activators intact, might provide a mechanism to regulate NF-B downstream genes without ablating basal levels.
Effect of NF-B Inhibition on Pulmonary Function. These data indicated a significant attenuation of the typical increase in CPB/DHCA-associated PVR by suppressing the elevation in NF-B activity with SN50. The reduction in PVR was associated with a marked reduction in the elevated levels of endothelin-1 detected in untreated animals undergoing CPB/ DHCA. Interestingly, these changes were similar to those seen with calpain inhibition (3) . Little is known about the role of This study demonstrated a significant benefit of SN50 on myocardial function as well as clinically relevant signs of cardiac output. Blocking the rise in NF-B associated with CPB/DHCA resulted in both improved systolic and diastolic function measured by maximum and minimum dP/dt, tau, and preload recruitable stroke work. Furthermore, the reduction in cardiac dysfunction was associated with improved oxygen delivery and would be considered relevant in the clinical setting. The data are in agreement with prior studies that showed inhibition of NF-B attenuates inflammation and apoptosis associated with myocardial ischemia and reperfusion (27) .
Effect of NF-B Inhibition on Markers of Myocardial Injury. Troponin is a major contractile protein in the mammalian heart that is a target for calpain proteolytic activity. Inhibition of calpain activity prevents TnI degradation in the rodents' hearts (28, 29) and in this model (1) . This study demonstrated a reduction in both total TnI degradation products and the major 26-kD degradation product in SN50-treated animals. However, calpain cleavage of TnI was thought to be a direct proteolytic effect and not necessarily related to NF-B. Nonetheless, in this study, NF-B inhibition resulted in decreased TnI degradation and was associated with preservation of calpastatin levels, indicating a possible regulation of calcium-dependent calpain activity by NF-B. Reducing calcium influx could modulate cardiomyocyte calpain activity and the calpain-mediated degradation of calpastatin. The higher calpastatin levels with NF-B inhibition might then be protective of troponin proteins susceptible to calpain degradation. Modalities that preserve intact myofilament proteins may reduce myocardial dysfunction after reperfusion.
NF-B Mediation of Calpain Activation. There are very limited indications that NF-B can affect calpain activation, possibly through regulation of calcium influx. NF-B can suppress expression of Cav1.2 calcium channels in smooth muscle cells with kappaB binding sites on the Ltype calcium channel gene that prevent the contractile response to acetylcholine (30) . In addition, NF-B binds the promoter of the transient receptor potential channel 1 gene in endothelial cells, which induces calcium influx after depletion of intracellular calcium stores (31) . These mechanisms of NF-B calcium regulation might provide a link for NF-B mediation of calpain activity, higher calpastatin levels in the heart, and NF-B's reduction in TnI degradation.
CONCLUSIONS
The multifactorial activation of NF-B alters gene expression not only between cell types but also within the same cells depending on environmental conditions. The dose of SN50 in this study was chosen for partial, not complete, blockade of NF-B activity. Potential therapeutics directed at mediating NF-B-induced gene expression should minimize but not ablate NF-B activation. Calpain-mediated IB␣ degradation may be a potential therapeutic target to reduce detrimental NF-B-activated responses to ischemia and reperfusion without stimulating cell injury with total blockade.
